ADHD

A large 2026 meta-analysis found no association between prenatal paracetamol (acetaminophen) use and autism, ADHD, or intellectual disability in children.

The investigational compound centanafadine to treat ADHD in children, adults, and adolescents, is a first-in-class NDSRI.

High-dose centanafadine significantly improved ADHD symptoms in children aged 6 to 12 years and was well tolerated, according to findings from a phase 3 clinical trial.

Explore essential resources and toolkits for managing the ongoing stimulant medication shortage affecting ADHD treatment and patient care.

Findings may help guide clinicians and policymakers in balancing the risks and benefits of stimulant prescribing in adolescent populations, according to the study authors.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

"My takeaway is that if medicine is needed, stimulants will be my first choice in this age group, regardless of whether the ADHD coexists with ASD."

Digital therapeutics help kids build emotional regulation and coping skills, supporting pediatric care while waiting for specialized mental health services.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The once daily extended-release oral suspension with nighttime dosing is approved to treat ADHD as a monotherapy or as an adjunctive therapy to approved CNS stimulant medications.

New international findings show BPD diagnosis in teenaged years may be a critical indicator of subsequent mental disorder into young adulthood.

According to a recent study, young adults (aged 18-19 years) discontinue ADHD medication the most, compared to younger children.

To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).

A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.

A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.

Lisdexamfetamine dimesaylate was associated with reduced ADHD symptoms in children aged 4 to 5 years.

Drs Robert L. Findling and Timothy Wilens discuss the efficacy and safety data of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) in childhood ADHD.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, review serdexmethylphenidate-dexmethylphenidate, a combination agent recently approved for the treatment of ADHD.

Jeffrey L. Alvaro, M.D., introduces an upcoming panel discussion surrounding the clinical implications of novel drug delivery systems in the management of Pediatric ADHD, utilizing 3 patient cases.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, consider the dosing and adherence challenges that arise in pediatric ADHD, as well as the potential benefits and damages of patients taking a break from treatment.